REPORT FROM THE 9th INTERNATIONAL CONFERENCE AD/PD, PRAGUE, CZECH REPUBLIC, MARCH 11-15, 2009 – A single-centre open trial in Sweden has compared the use of galantamine and risperidone for the treatment of behavioural and psychological symptoms in dementia (BPSD) (Freund-Levi. AD/PD; 1290).
Neurology
Diabetes a risk factor for MCI, Alzheimers disease
August 11, 2009REPORT FROM THE 9th INTERNATIONAL CONFERENCE AD/PD, PRAGUE, CZECH REPUBLIC, MARCH 11-15, 2009 – German researchers have analysed data from the Longitudinal Study on Adult Development and Aging to assess the impact of type 2 diabetes on the development of mild cognitive impairment (MCI) and Alzheimers disease (Toro et al. AD/PD; 427; published as Toro et al. J Alzheimers Dis 2009;16: 687-691)). All subjects were born in the period 1930-1932.
Alzheimer’s disease and HMG CoA reductase variants
August 11, 2009REPORT FROM THE 9th INTERNATIONAL CONFERENCE AD/PD, PRAGUE, CZECH REPUBLIC, MARCH 11-15, 2009 – Genetic variants in HMG CoA reductase may influence the risk of Alzheimers disease, according to the results of a study of French Canadians from Eastern Canada (Legault et al. AD/PD; 1626).
Predictors of response: results from long-term follow-up
July 21, 2009REPORT FROM THE 2009 AAN ANNUAL MEETING – Early progression of disability, a high relapse rate and ongoing MRI activity appear to be indicators of an inadequate response to disease-modifying therapy, according to the 15-year follow-up results of the MS Collaborative Study Group pivotal trial of beta-interferon-1a (Avonex) (Bermel et al. AAN 2009; abstract P02.117).
Read More
Prospective trial of vitamin D in MS
July 21, 2009
Leave a reply
REPORT FROM THE 2009 AAN ANNUAL MEETING – High-dose vitamin D3 supplementation appears to be well tolerated and significantly reduces T cell reactivity, according to the results of a prospective Canadian trial (Burton et al. AAN 2009; abstract P01.110).
Read More